Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 24;12(9):2045.
doi: 10.3390/diagnostics12092045.

Differentiating Polycystic Ovary Syndrome from Adrenal Disorders

Mert Yesiladali  1 , Melis G K Yazici  1 , Erkut Attar  1 , Fahrettin Kelestimur  2
Affiliations
Review

Differentiating Polycystic Ovary Syndrome from Adrenal Disorders

Mert Yesiladali et al. Diagnostics (Basel). .

Abstract

Although polycystic ovary syndrome (PCOS) is primarily considered a hyperandrogenic disorder in women characterized by hirsutism, menstrual irregularity, and polycystic ovarian morphology, an endocrinological investigation should be performed to rule out other hyperandrogenic disorders (e.g., virilizing tumors, non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, and Cushing's syndrome) to make a certain diagnosis. PCOS and androgen excess disorders share clinical features such as findings due to hyperandrogenism, findings of metabolic syndrome, and menstrual abnormalities. The diagnosis of a woman with these symptoms is generally determined based on the patient's history and rigorous clinical examination. Therefore, distinguishing PCOS from adrenal-originated androgen excess is an indispensable step in diagnosis. In addition to an appropriate medical history and physical examination, the measurement of relevant basal hormone levels and dynamic tests are required. A dexamethasone suppression test is used routinely to make a differential diagnosis between Cushing's syndrome and PCOS. The most important parameter for differentiating PCOS from NCAH is the measurement of basal and ACTH-stimulated 17-OH progesterone (17-OHP) when required in the early follicular period. It should be kept in mind that rapidly progressive hyperandrogenic manifestations such as hirsutism may be due to an androgen-secreting adrenocortical carcinoma. This review discusses the pathophysiology of androgen excess of both adrenal and ovarian origins; outlines the conditions which lead to androgen excess; and aims to facilitate the differential diagnosis of PCOS from certain adrenal disorders.

Keywords: Cushing’s syndrome; adrenal tumor; androgen excess disorder; non-classical congenital adrenal hyperplasia; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Steroidogenesis pathways in adrenals and ovaries. P450 SCC: side chain cleavage enzyme, 3β-HSD: 3β-Hydroxysteroid dehydrogenase, 17β-HSD: 17 beta hydroxysteroid dehydrogenase.
Figure 2
Figure 2
Sources of serum androgens in healthy women.
Figure 3
Figure 3
Clinical findings in CS and PCOS.
Figure 4
Figure 4
A differential diagnosis algorithm for hyperandrogenism.
See this image and copyright information in PMC

References

    1. Riestenberg C., Jagasia A., Markovic D., Buyalos R.P., Azziz R. Health care-related economic burden of polycystic ovary syndrome in the United States: Pregnancy-related and long-term health consequences. J. Clin. Endocrinol. Metab. 2022;107:575–585. doi: 10.1210/clinem/dgab613. - DOI - PubMed
    1. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H., Franks S., Gambineri A., Kelestimur F., Macut D., Micic D., Pasquali R., et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014;171:P1–P29. doi: 10.1530/EJE-14-0253. - DOI - PubMed
    1. Yildiz B.O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 2012;27:3067–3073. doi: 10.1093/humrep/des232. - DOI - PubMed
    1. Della Corte L., Foreste V., Barra F., Gustavino C., Alessandri F., Centurioni M.G., Ferrero S., Bifulco G., Giampaolino P. Current and experimental drug therapy for the treatment of polycystic ovarian syndrome. Expert Opin. Investig. Drugs. 2020;29:819–830. doi: 10.1080/13543784.2020.1781815. - DOI - PubMed
    1. Celik O., Yildiz B.O. Adrenal and Polycystic Ovary Syndrome. Cambridge University Press; Cambridge, UK: 2022. p. 67.

LinkOut - more resources